AI Engines For more Details: Perplexity Kagi Labs You
Digestive Health: Like other Bacillus species, Bacillus pumilus may contribute to digestive health by modulating the gut microbiota. Probiotics like Bacillus pumilus may help maintain a balanced microbial community in the intestines, promote the production of beneficial metabolites, and support digestive function, potentially reducing the risk of gastrointestinal disorders such as diarrhea, constipation, and inflammatory bowel diseases (IBD).
Immune Modulation: Bacillus pumilus may have immunomodulatory effects, stimulating the production of immune cells and enhancing the body's defense mechanisms against infections and diseases. By promoting immune tolerance and regulating inflammatory responses, probiotics like Bacillus pumilus may help strengthen the immune system and reduce the risk of immune-related conditions such as allergies, autoimmune diseases, and infections.
Antimicrobial Activity: Some strains of Bacillus pumilus produce antimicrobial compounds that inhibit the growth of harmful bacteria and pathogens. This antimicrobial activity may help prevent the colonization of pathogenic microorganisms in the gut and reduce the risk of infections, particularly those associated with antibiotic use and dysbiosis.
Nutrient Production: Bacillus pumilus has the potential to produce various beneficial metabolites, including vitamins, enzymes, and short-chain fatty acids. These metabolites may have positive effects on overall health and metabolism, supporting nutrient absorption, energy metabolism, and gut-brain axis communication.
Environmental Adaptability: Bacillus pumilus is known for its environmental resilience and adaptability to diverse conditions, including extreme temperatures, pH levels, and salinity. These characteristics may translate to potential health benefits, as probiotics with robust survival mechanisms are more likely to withstand the harsh conditions of the gastrointestinal tract and exert their effects in the gut microbiota.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bifidobacterium adolescentis | Increases |
| species | Bifidobacterium bifidum | Increases |
| species | Bifidobacterium breve | Increases |
| species | Bifidobacterium catenulatum | Increases |
| species | Bifidobacterium longum | Increases |
| species | Bifidobacterium pseudocatenulatum | Increases |
| species | Lactobacillus acidophilus | Increases |
| species | Lactobacillus crispatus | Increases |
| species | Lactobacillus gasseri | Increases |
| species | Lactobacillus helveticus | Increases |
| species | Lactobacillus jensenii | Increases |
| species | Lactobacillus johnsonii | Increases |
| species | Lactobacillus kefiranofaciens | Increases |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 1.8 | 0.3 | 5 |
| ADHD | 1.8 | 2.8 | -0.56 |
| Age-Related Macular Degeneration and Glaucoma | 0.3 | 0.3 | 0 |
| Allergic Rhinitis (Hay Fever) | 2.1 | 0.2 | 9.5 |
| Allergies | 3.2 | 2.3 | 0.39 |
| Allergy to milk products | 1.5 | 2.9 | -0.93 |
| Alopecia (Hair Loss) | 0.9 | 0.9 | |
| Alzheimer's disease | 4.9 | 4.8 | 0.02 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.3 | 2 | 0.15 |
| Ankylosing spondylitis | 2.9 | 1.7 | 0.71 |
| Anorexia Nervosa | 1.7 | 0.8 | 1.13 |
| Antiphospholipid syndrome (APS) | 0.2 | 0.2 | |
| Asthma | 2.1 | 1.6 | 0.31 |
| Atherosclerosis | 0.6 | 2.4 | -3 |
| Atrial fibrillation | 3.1 | 2.5 | 0.24 |
| Autism | 6 | 5.8 | 0.03 |
| benign prostatic hyperplasia | 0.6 | 0.6 | |
| Bipolar Disorder | 1.5 | 2.5 | -0.67 |
| Brain Trauma | 2.1 | 0.9 | 1.33 |
| Breast Cancer | 0.1 | 0.1 | |
| Carcinoma | 2.5 | 2.3 | 0.09 |
| Celiac Disease | 3.8 | 1.8 | 1.11 |
| Cerebral Palsy | 1.2 | 1.1 | 0.09 |
| Chronic Fatigue Syndrome | 2.2 | 2.7 | -0.23 |
| Chronic Kidney Disease | 2.1 | 0.8 | 1.63 |
| Chronic Lyme | 0.5 | 0.5 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.6 | 0.5 | 0.2 |
| Chronic Urticaria (Hives) | 1.2 | 1.2 | |
| Coagulation / Micro clot triggering bacteria | 1.9 | 0.5 | 2.8 |
| Colorectal Cancer | 3 | 1.7 | 0.76 |
| Constipation | 2.1 | 0.8 | 1.63 |
| Coronary artery disease | 0.4 | 1.9 | -3.75 |
| COVID-19 | 6.5 | 4.9 | 0.33 |
| Crohn's Disease | 6.4 | 4.8 | 0.33 |
| cystic fibrosis | 1.8 | 1.8 | |
| deep vein thrombosis | 1.9 | 1.9 | |
| Depression | 6 | 6.7 | -0.12 |
| Dermatomyositis | 0.6 | 0.6 | |
| Eczema | 2.3 | 1.1 | 1.09 |
| Endometriosis | 3.3 | 2 | 0.65 |
| Epilepsy | 3.6 | 2.5 | 0.44 |
| erectile dysfunction | 0.6 | 0.6 | |
| Fibromyalgia | 2.2 | 0.6 | 2.67 |
| Functional constipation / chronic idiopathic constipation | 3.1 | 3.4 | -0.1 |
| gallstone disease (gsd) | 2 | 1.5 | 0.33 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | 0.3 | -0.5 |
| Generalized anxiety disorder | 1.6 | 0.5 | 2.2 |
| giant cell arteritis | 0.3 | -0.3 | |
| Glioblastoma | 0.9 | 0.3 | 2 |
| Gout | 0.8 | -0.8 | |
| Graves' disease | 2.5 | -2.5 | |
| Hashimoto's thyroiditis | 2.3 | 1.2 | 0.92 |
| Hemorrhoidal disease, Hemorrhoids, Piles | 0.6 | -0.6 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.3 | 1.5 | -4 |
| hypercholesterolemia (High Cholesterol) | 0.6 | 0.6 | |
| hyperglycemia | 2 | 1.1 | 0.82 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.6 | 0.5 |
| hypersomnia | 0.5 | -0.5 | |
| hypertension (High Blood Pressure | 3 | 3.3 | -0.1 |
| Hypothyroidism | 2.7 | 1.6 | 0.69 |
| Hypoxia | 0.6 | -0.6 | |
| IgA nephropathy (IgAN) | 2.6 | 0.2 | 12 |
| Inflammatory Bowel Disease | 4.3 | 3 | 0.43 |
| Insomnia | 1.4 | 0.8 | 0.75 |
| Intelligence | 1.5 | 1.1 | 0.36 |
| Intracranial aneurysms | 1.7 | 0.9 | 0.89 |
| Irritable Bowel Syndrome | 3.9 | 2.5 | 0.56 |
| Liver Cirrhosis | 5.8 | 3.5 | 0.66 |
| Long COVID | 7.4 | 4.6 | 0.61 |
| Low bone mineral density | 1.1 | 0.8 | 0.38 |
| Lung Cancer | 1.4 | 0.8 | 0.75 |
| ME/CFS with IBS | 1.4 | 0.5 | 1.8 |
| ME/CFS without IBS | 0.6 | 0.5 | 0.2 |
| Menopause | 0.4 | 0.4 | 0 |
| Metabolic Syndrome | 7.2 | 5.8 | 0.24 |
| Mood Disorders | 6.8 | 8.8 | -0.29 |
| multiple chemical sensitivity [MCS] | 0.2 | 1.1 | -4.5 |
| Multiple Sclerosis | 3.3 | 2.5 | 0.32 |
| Multiple system atrophy (MSA) | 1.4 | 1.1 | 0.27 |
| myasthenia gravis | 0.3 | 0.5 | -0.67 |
| Neuropathy (all types) | 0.8 | 0.8 | 0 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.3 | 1 |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.7 | 1.7 | 1.76 |
| NonCeliac Gluten Sensitivity | 0.6 | 0.6 | |
| Obesity | 6.5 | 4.5 | 0.44 |
| obsessive-compulsive disorder | 3.8 | 2.6 | 0.46 |
| Osteoarthritis | 2.6 | 2.6 | |
| Osteoporosis | 1.5 | 2.3 | -0.53 |
| pancreatic cancer | 0.3 | -0.3 | |
| Parkinson's Disease | 4 | 4.7 | -0.18 |
| Polycystic ovary syndrome | 3 | 1.7 | 0.76 |
| Postural orthostatic tachycardia syndrome | 1.1 | 0.5 | 1.2 |
| Premenstrual dysphoric disorder | 1.1 | 0.6 | 0.83 |
| primary biliary cholangitis | 0.6 | 0.6 | |
| Psoriasis | 0.5 | 2.9 | -4.8 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5 | 6.5 | -0.3 |
| Rosacea | 0.6 | 1.4 | -1.33 |
| Schizophrenia | 2.9 | 3.9 | -0.34 |
| scoliosis | 1.4 | 0.3 | 3.67 |
| sensorineural hearing loss | 0.3 | -0.3 | |
| Sjögren syndrome | 3 | 1.8 | 0.67 |
| Sleep Apnea | 2.3 | 3.1 | -0.35 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 0.3 | 2 |
| Stress / posttraumatic stress disorder | 2.7 | 1.9 | 0.42 |
| Systemic Lupus Erythematosus | 4.8 | 1.6 | 2 |
| Tic Disorder | 0.8 | 1.5 | -0.88 |
| Tourette syndrome | 0.9 | 0.9 | |
| Type 1 Diabetes | 3 | 0.6 | 4 |
| Type 2 Diabetes | 6.3 | 5.3 | 0.19 |
| Ulcerative colitis | 4 | 3.6 | 0.11 |
| Unhealthy Ageing | 3 | 1.1 | 1.73 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.